Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer radiotherapeutics - Algeta

Drug Profile

Research programme: cancer radiotherapeutics - Algeta

Alternative Names: 227Th conjugates; FGFR2-targeted thorium-227 conjugate; HER2-targeted thorium-227 conjugate; Targeted thorium conjugates - Algeta; TH-1 programme; thorium-227 conjugates; TTC - Algeta

Latest Information Update: 28 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Algeta
  • Developer Algeta; Norwegian Radium Hospital
  • Class Antibodies; Drug conjugates; Monoclonal antibodies; Peptides; Proteins; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Glutamate carboxypeptidase II inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Feb 2023 NDR batch #29 - Retain the NDR as it is for preclinical development in Cancer in Norway (Parenteral, Injection) as company website is not accessible. And did not get nay info about it on free google search
  • 28 Apr 2019 No recent reports of development identified for preclinical development in Cancer in Norway (Parenteral, Injection)
  • 22 Mar 2017 Preclinical development is ongoing in Norway
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top